Product Information
RIVASTIGMINE 13.3 MG/24HR PTCH is a generic product labeled by Amneal Pharmaceuticals LLC, priced at $1.7959 per EA under NDC 65162074934. Its NADAC has been published 391 times since Apr 10, 2019.
FDA first approved this application on Jan 8, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
13.3 mg/24h
Manufacturer
Amneal Pharmaceuticals LLCNDC
65162074934
Classification
Generic
Dosage Form
PATCH
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
RIVASTIGMINEApproval Type
Generic (ANDA)
FDA Application
ANDA207308FDA Approved
1/8/2019
TE Code
AB
On Market Since
6/30/2015
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has been published 391 times since Apr 10, 2019, and over the history we have for it it has declined 62.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7959 per EA |
|---|---|
| All-time high | $5.3640 (Aug 14, 2019) |
| All-time low | $1.6436 (Apr 17, 2024) |
| 52-week high | $2.0633 |
| 52-week low | $1.7959 |
| Median price | $2.6490 |
| Average price | $2.8561 |
| Largest weekly change | -33.3% (Apr 17, 2024) |
| Weeks tracked | 391 |
| Tracking since | Apr 10, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rivastigmine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 13.3 MG/24HR PTCH?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 13.3 MG/24HR PTCH, manufactured by Amneal Pharmaceuticals LLC, is $1.7959 per EA (NDC 65162074934), effective Sep 30, 2026.
How has the price of RIVASTIGMINE 13.3 MG/24HR PTCH changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has declined 62.6%. It has been tracked across 391 weekly CMS publications since Apr 10, 2019.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 13.3 MG/24HR PTCH?
Since Apr 10, 2019, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has ranged from a low of $1.6436 (Apr 17, 2024) to a high of $5.3640 (Aug 14, 2019), with a median of $2.6490 per EA.
Are there cheaper alternatives to RIVASTIGMINE 13.3 MG/24HR PTCH?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 13.3 MG/24HR PTCH in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 13.3 MG/24HR PTCH?
RIVASTIGMINE 13.3 MG/24HR PTCH (NDC 65162074934) is labeled by Amneal Pharmaceuticals LLC, and CMS classifies it as a generic product.